Page 1693 - Williams Hematology ( PDFDrive )

1668 Part XI: Malignant Lymphoid Diseases Chapter 101: Marginal Zone B-cell Lymphomas 1669

REFERENCES

1. Swerdlow SH, Campo E, Harris NL, et al. (eds): World Health Organization Classification of
Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, 2008.
2. Berger F, Felman P, Thieblemont C, et al: Non-MALT marginal zone B-cell lympho-
mas: A description of clinical presentation and outcome in 124 patients. Blood 95:
1950–1956, 2000.
3. Arcaini L, Lucioni M, Boveri E, Paulli M: Nodal marginal zone lymphoma: Current
knowledge and future directions of an heterogeneous disease. Eur J Haematol 83:
165–174, 2009.
4. Ferreri AJ, Dolcetti R, Magnino S, et al: Chlamydial infection: The link with ocular
adnexal lymphomas. Nat Rev Clin Oncol 6:658–669, 2009.
5. Lecuit M, Abachin E, Martin A, et al: Immunoproliferative small intestinal disease
associated with Campylobacter jejuni. N Engl J Med 350:239–248, 2004.
6. Zucca E, Roggero E, Maggi-Solcà N, et al: Prevalence of Helicobacter pylori and
hepatitis C virus infection among non-Hodgkin’s lymphoma patients in southern
Switzerland. Haematologica 85:147–153, 2000.
7. Roggero E, Zucca E, Mainetti C, et al: Eradication of Borrelia burgdorferi infection in
primary marginal zone B-cell lymphoma of the skin. Hum Pathol 31:263–268, 2000.
8. O’Rourke JL: Gene expression profiling in Helicobacter-induced MALT lymphoma
with reference to antigen drive and protective immunization. J Gastroenterol Hepatol
23(Suppl):S151–S156, 2008.
Figure 101–2. Nodal marginal zone lymphoma (Giemsa stain, magni- 9. Ponzoni M, Ferreri AJ, Guidoboni M, et al: Chlamydia infection and lymphomas: Asso-
fication ×200). (Used with permission of Dr. Claudio Agostinelli.) ciation beyond ocular adnexal lymphomas highlighted by multiple detection methods.
Clin Cancer Res 14:5794–5800, 2008.
10. Derringer GA, Thompson LD, Frommelt RA, et al: Malignant lymphoma of the thyroid
gland: A clinicopathologic study of 108 cases. Am J Surg Pathol 24:623–639, 2000.
in which case marked plasmacytoid differentiation and a nodular or 11. Manganelli P, Fietta P, Quaini F: Hematologic manifestations of primary Sjögren’s syn-
drome. Clin Exp Rheumatol 24:438–448, 2006.
follicular growth pattern mimicking follicular lymphoma is often seen 12. Dierlamm J, Baens M, Wlodarska I, et al: The apoptosis inhibitor gene API2 and a
(Fig. 101–2). novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated
with mucosa-associated lymphoid tissue lymphoma. Blood 93:3601–3609, 1999.
13. Kwee I, Rancoita PM, Rinaldi A, et al: Genomic profiles of MALT lymphomas: Variabil-
ity across anatomical sites. Haematologica 96:1064–1066, 2011.
DIFFERENTIAL DIAGNOSIS 14. Troch M, Kiesewetter B, Raderer M: Recent developments in nongastric mucosa-
associated lymphoid tissue lymphoma. Curr Hematol Malig Rep 6:216–221, 2011.
Pediatric NMZL is a different clinical entity that arises in adolescent 15. Dreyling M, Thieblemont C, Gallamini A, et al: ESMO consensus conferences:
patients, with a striking predominance in males. Atypical cells within Guidelines on malignant lymphoma. Part 2: Marginal zone lymphoma, mantle cell
lymph nodes show a marked pleomorphism and an interfollicular dis- lymphoma, peripheral T-cell lymphoma. Ann Oncol 24:857–877, 2013.
tribution with marginal zones considerably expanded. Patients gen- 16. Chey WD, Wong BC: American College of Gastroenterology guideline on the manage-
1
ment of Helicobacter pylori infection. Am J Gastroenterol 102:1808–1825, 2007.
erally present with localized stage I disease, which can be managed 17. Zinzani PL, Tani M, Barbieri E, et al: Utility of surgical resection with or without radia-
conservatively (surgical excision and observation), with low rates of tion therapy in patients with low-grade mucosa-associated lymphoid tissue lymphoma.
disease recurrence. Haematologica 88:830–831, 2003.
The pathologic distinction between NMZL, LPL and follicular 18. Yahalom J: MALT lymphomas: A radiation oncology view-point. Ann Hematol
80(Suppl 3):B100–B105, 2001.
lymphoma with marginal zone differentiation can be difficult. Immuno- 19. Koch P, Probst A, Berdel WE, et al: Treatment results in localized primary gastric lym-
histochemistry may be a useful diagnostic tool by demonstrating BCL6 phoma: Data of patients registered within the German multicenter study (GIT NHL
02/96). J Clin Oncol 23:7050–7059, 2005.
and CD10 expression in follicular lymphoma, whereas the demonstra- 20. Hammel P, Haioun C, Chaumette MT, et al: Efficacy of single-agent chemotherapy in
tion of a large IgM paraprotein spike in the serum suggests LPL rather low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric
than NMZL. expression. J Clin Oncol 13:2524–2529, 1995.
21. Avilés A, Nambo MJ, Neri N, et al: Mucosa-associated lymphoid tissue (MALT) lym-
phoma of the stomach: Results of a controlled clinical trial. Med Oncol 22:57–62, 2005.
22. Jäger U, Neumeister P, Quehenberger F, et al: Prolonged clinical remission in patients
THERAPY with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid
tissue type treated with cladribine: 6 year follow-up of a phase II trial. Ann Oncol
No specific treatment consensus guidelines have been developed for 17:1722–1723, 2006.
NMZL, and patients are generally well managed according to treatment 23. Martinelli G, Laszlo D, Ferreri A, et al: Clinical activity of rituximab in gastric marginal
paradigms developed for follicular lymphoma and other indolent NHLs. zone non-Hodgkin’s lymphoma resistant to or not eligible for anti-Helicobacter pylori
therapy. J Clin Oncol 23:1979–1983, 2005.
In limited stage disease, surgery and radiotherapy are often appropriate, 24. Raderer M, Chott A, Drach J, et al: Chemotherapy for management of localised high
whereas immunochemotherapy is the most suitable option for patients grade gastric B-cell lymphoma: How much is necessary? Ann Oncol 13:1094–1098,
presenting with symptomatic advanced stage disease. 15,46 Patients with 2002.
concomitant HCV infection and no urgency for lymphoma treatment 25. Conconi A, Martinelli G, Lopez-Guillermo A, et al: Clinical activity of bortezomib in
relapsed/refractory MALT lymphomas: Results of a phase II study of the International
should receive antiviral treatment with interferon and ribavirin. High- Extranodal Lymphoma Study Group (IELSG). Ann Oncol 22:689–695, 2011.
47
dose therapy and autologous stem cell transplantation can be considered 26. Salar A, Domingo E, Canales M, et al: Bendamustine and rituximab as first line treat-
for patients with aggressive presentations and short remission durations ment for patients with MALT lymphoma. An interim report of a phase 2 trial in Spain
(GELTAMO MALT-2008–01). Ann Oncol 22(Suppl 4):IV184, 2011.
following standard immunochemotherapy regimens. 46 27. Zinzani PL, Stefoni V, Musuraca G, et al: Fludarabine-containing chemotherapy as
frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lym-
phoma. Cancer 100:2190–2194, 2004.
COURSE AND PROGNOSIS 28. Zinzani PL, Pellegrini C, Broccoli A, et al: Fludarabine-mitoxantrone-rituximab regi-
men in untreated indolent non-follicular non-Hodgkin’s lymphoma: Experience on 143
The average 5-year survival of NMZL is approximately 60 to 70 percent, patients. Hematol Oncol 2014, in press. DOI: 10.1002/hon.2151. [Epub ahead of print]
with an estimated 5-year event-free survival of nearly 30 percent, thus 29. Zucca E, Conconi A, Laszlo D, et al: Addition of rituximab to chlorambucil produces
indicating a high tendency of disease to relapse over time, albeit with superior event-free survival in the treatment of patients with extranodal marginal-
zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol
rare involvement of extranodal sites. 31:565–572, 2013.

Kaushansky_chapter 101_p1663-1670.indd 1668 9/18/15 9:37 AM